Providers

Older adults with cardiovascular disease (CVD) or CVD risk factors report that gaps in communication among their providers are common and hazardous.

Trastuzumab deruxtecan plus pertuzumab shows promising results as a potential new first-line treatment for HER2-positive breast cancer at ASCO 2025.

Researchers found a causal association between insomnia and atopic dermatitis and identified several genetic variations contributing to the association.

Fecal immunochemical testing (FIT) was more accurate than blood-based testing for detecting advanced precancerous colorectal lesions, a comparative study found.

Iron deficiency anemia increased the risk of death from any cause, while non-iron deficiency anemia was linked with an increased risk of cardiovascular disease (CVD)-related death in rheumatoid arthritis.

Advancements in gene therapy for Duchenne muscular dystrophy (DMD) have improved the outlook for some patients, but further innovations in safety, efficacy, and treatment strategies are needed.

Genetic testing for hereditary cancer unexpectedly uncovers a case of myelodysplastic syndrome (MDS), highlighting the need for careful interpretation of results and multidisciplinary collaboration.

A new device was able to distinguish between mild and very severe chronic obstructive pulmonary disease (COPD).

The findings suggest assessment of CD20 may be an important factor in determining treatment options in B-cell lymphomas.

The rate of rheumatoid arthritis (RA) has increased over the last 32 years, with certain groups of interest facing higher burden, finds a new analysis.

New findings suggest that reducing the variant allele frequency of JAK2V617F should be a goal of treatment for polycythemia vera.

Delandistrogene moxeparvovec, a gene therapy for Duchenne muscular dystrophy (DMD), showed high dystrophin expression and a favorable safety profile in young patients.

Elevated LDH and higher international prognostic index were also predictors of poor outcomes on bispecific antibodies, investigators found.

New research reveals light sensitivity significantly impacts quality of life in myasthenia gravis patients, highlighting the need for targeted treatment strategies.

The findings, which add to the limited data on the burden of atopic dermatitis on adolescent and pediatric patients, showed differences in what was most bothersome to the younger group of patients.

Patients with extensive-stage small cell lung cancer (SCLC) experienced clinically meaningful benefits with lurbinectedin plus atezolizumab vs atezolizumab in the phase 3 IMforte trial, according to findings being presented at the ASCO Annual Meeting.

Luspatercept showed real-world efficacy among patients with lower-risk myelodysplastic syndrome (MDS), confirming results seen in clinical trials.

Even a 2% decline in lung function predicted poor outcomes for patients with idiopathic pulmonary fibrosis (IPF) in a new study.

The tool could make it easier for clinicians to rule out melanoma without the need for excision.

The real-world data showed lower rates of atrial fibrillation and hypertension associated with the second-generation Bruton tyrosine kinase inhibitor among patients with chronic lymphocytic leukemia (CLL).

A systematic review and subsequent expert review gave comprehensive insight into prognostic factors for patients receiving treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

The meta-analysis of 9 studies showed high sensitivity with slightly lower specificity with the less-invasive option for detecting lung complications in patients with the autoimmune disease.

The combination of antifibrotic therapy and pulmonary vasodilator therapy improved transplant-free survival but had no significant impact on exercise capacity in pulmonary fibrosis and pulmonary hypertension.

A significant number of patients taking Bruton tyrosine kinase inhibitors (BTKis) for chronic lymphocytic leukemia (CLL) develop atrial fibrillation (AF).

Two studies explored the quality-of-life impacts of lebrikizumab for atopic dermatitis, finding its benefits extend beyond physical symptom improvements.

Despite holding promise in a range of disease states, a variety of challenges prevent cell and gene therapies (CGTs) from more widespread use, according to a new report from Cardinal Health.

The study, which used flow cytometry rather than molecular biology to identify circulating tumor cells (CTCs), found a significant positive correlation between the number of CTCs and the stage of disease.

Delandistrogene moxeparvovec (Elevidys; Sarepta Therapeutics) appeared to protect muscle from progressive damage in patients with Duchenne muscular dystrophy (DMD) based on muscle quantitative magnetic resonance measures.

Remote symptom monitoring in cancer care reduces hospitalizations, enhances value-based care, and supports diverse patient populations, according to new findings.

Across various classes, the researchers identified a model that, when coupled with appropriate data augmentation and optimization partner, may help aid in the detection of skin cancer.